Analyzing Stevanato Group (STVN) and Its Competitors

Stevanato Group (NYSE:STVN) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its competitors? We will compare Stevanato Group to similar businesses based on the strength of its earnings, profitability, risk, valuation, institutional ownership, dividends and analyst recommendations.

Profitability

This table compares Stevanato Group and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Stevanato Group Competitors	-540.59%	-166.46%	-13.58%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Stevanato Group and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0	5	2	2	2.67
Stevanato Group Competitors	947	3162	5476	177	2.50

As a group, “Life Sciences Tools & Services” companies have a potential downside of 4.10%. Given Stevanato Group’s competitors higher possible upside, analysts plainly believe Stevanato Group has less favorable growth aspects than its competitors.

Risk and Volatility

Stevanato Group has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Stevanato Group’s competitors have a beta of 0.94, meaning that their average share price is 6% less volatile than the S&P 500.

Valuation and Earnings

This table compares Stevanato Group and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Stevanato Group	$1.34 billion	$158.21 million	22.49
Stevanato Group Competitors	$2.26 billion	$55.88 billion	-13.91

Stevanato Group’s competitors have higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

54.4% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 15.2% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Stevanato Group competitors beat Stevanato Group on 7 of the 13 factors compared.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.